<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Environ Res Public Health</journal-id><journal-id journal-id-type="iso-abbrev">Int J Environ Res Public Health</journal-id><journal-id journal-id-type="pmc-domain-id">876</journal-id><journal-id journal-id-type="pmc-domain">ijerph</journal-id><journal-id journal-id-type="publisher-id">ijerph</journal-id><journal-title-group><journal-title>International Journal of Environmental Research and Public Health</journal-title></journal-title-group><issn pub-type="ppub">1661-7827</issn><issn pub-type="epub">1660-4601</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10094391</article-id><article-id pub-id-type="pmcid-ver">PMC10094391.1</article-id><article-id pub-id-type="pmcaid">10094391</article-id><article-id pub-id-type="pmcaiid">10094391</article-id><article-id pub-id-type="pmid">37047987</article-id><article-id pub-id-type="doi">10.3390/ijerph20075373</article-id><article-id pub-id-type="publisher-id">ijerph-20-05373</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>A Comparison between Perceptions of Psychiatric Outpatients and Psychiatrists Regarding Benzodiazepine Use and Decision Making for Its Discontinuation: A Cross-Sectional Survey in Japan</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Aoki</surname><given-names initials="Y">Yumi</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><xref rid="af1-ijerph-20-05373" ref-type="aff">1</xref><xref rid="af2-ijerph-20-05373" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0614-7524</contrib-id><name name-style="western"><surname>Takeshima</surname><given-names initials="M">Masahiro</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="af3-ijerph-20-05373" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tsuboi</surname><given-names initials="T">Takashi</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="af2-ijerph-20-05373" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9417-4391</contrib-id><name name-style="western"><surname>Katsumoto</surname><given-names initials="E">Eiichi</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="af4-ijerph-20-05373" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Udagawa</surname><given-names initials="K">Ken</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="af5-ijerph-20-05373" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Inada</surname><given-names initials="K">Ken</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af6-ijerph-20-05373" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Watanabe</surname><given-names initials="K">Koichiro</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af2-ijerph-20-05373" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1182-1181</contrib-id><name name-style="western"><surname>Mishima</surname><given-names initials="K">Kazuo</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af3-ijerph-20-05373" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Takaesu</surname><given-names initials="Y">Yoshikazu</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af2-ijerph-20-05373" ref-type="aff">2</xref><xref rid="af7-ijerph-20-05373" ref-type="aff">7</xref><xref rid="c1-ijerph-20-05373" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Maremmani</surname><given-names initials="I">Icro</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-ijerph-20-05373"><label>1</label>Psychiatric and Mental Health Nursing, St. Luke&#8217;s International University, Tokyo 104-0044, Japan</aff><aff id="af2-ijerph-20-05373"><label>2</label>Department of Neuropsychiatry, Kyorin University School of Medicine, Tokyo 181-8611, Japan</aff><aff id="af3-ijerph-20-05373"><label>3</label>Department of Neuropsychiatry, Akita University Graduate School of Medicine, Akita 010-8543, Japan</aff><aff id="af4-ijerph-20-05373"><label>4</label>Katsumoto Mental Clinic, Osaka 543-0056, Japan</aff><aff id="af5-ijerph-20-05373"><label>5</label>Community Mental Health &amp; Welfare Bonding Organization, Chiba 272-003, Japan</aff><aff id="af6-ijerph-20-05373"><label>6</label>Department of Psychiatry, Kitasato University School of Medicine, Kanagawa 252&#8211;0374, Japan</aff><aff id="af7-ijerph-20-05373"><label>7</label>Department of Neuropsychiatry, Graduate School of Medicine, University of the Ryukyus, Okinawa 903-0215, Japan</aff><author-notes><corresp id="c1-ijerph-20-05373"><label>*</label>Correspondence: <email>takaesuy@med.u-ryukyu.ac.jp</email></corresp></author-notes><pub-date pub-type="epub"><day>03</day><month>4</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2023</year></pub-date><volume>20</volume><issue>7</issue><issue-id pub-id-type="pmc-issue-id">432845</issue-id><elocation-id>5373</elocation-id><history><date date-type="received"><day>30</day><month>1</month><year>2023</year></date><date date-type="rev-recd"><day>14</day><month>3</month><year>2023</year></date><date date-type="accepted"><day>29</day><month>3</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>04</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>13</day><month>04</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-04-14 16:10:31.860"><day>14</day><month>04</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>&#169; 2023 by the authors.</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ijerph-20-05373.pdf"/><abstract><p>Background: Although long-term use of benzodiazepines and z-drugs (BZDs) is not recommended, little is known about the stakeholders&#8217; perceptions. This study aimed to assess and compare the perceptions of BZD use and decision making regarding its discontinuation between psychiatric outpatients and psychiatrists. Methods: A cross-sectional survey was conducted. Results: Of 104 outpatients, 92% were taking hypnotics and 96% were taking anxiolytics for &#8805;a year, while 49% were willing to taper hypnotic/anxiolytics within a year of starting. Most psychiatrists felt that &#8220;patient and psychiatrist make the decision together on an equal basis&#8221; compared to patients (<italic toggle="yes">p</italic> &lt; 0.001), while more patients felt that &#8220;the decision is (was) made considering the psychiatrists&#8217; opinion&#8221; compared to psychiatrists (<italic toggle="yes">p</italic> &lt; 0.001). Of 543 psychiatrists, 79% reported &#8220;patients were not willing to discontinue hypnotic/anxiolytic&#8221; whereas a certain number of patients conveyed &#8220;psychiatrists did not explain in enough detail about hypnotic/anxiolytic discontinuation such as procedure (18.3%), timing (19.2%), and appropriate condition (14.4%)&#8221;. Conclusion: The results suggest that the majority of psychiatric outpatients were taking hypnotic/anxiolytics for a long time against their will. There might be a difference in perceptions toward hypnotic/anxiolytic use and decision making for its discontinuation between psychiatric outpatients and psychiatrists. Further research is necessary to fill this gap.</p></abstract><kwd-group><kwd>benzodiazepine</kwd><kwd>cross-sectional survey</kwd><kwd>psychiatric outpatient</kwd><kwd>treatment decision making</kwd><kwd>shared decision making</kwd><kwd>Japan</kwd></kwd-group><funding-group><award-group><funding-source>The Ministry of Health, Labor and Welfare of Japan</funding-source><award-id>21GC1016</award-id></award-group><funding-statement>This study was supported by research grants from the Ministry of Health, Labor and Welfare of Japan (21GC1016).</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-ijerph-20-05373"><title>1. Introduction</title><p>Benzodiazepines and z-drugs (BZDs) act as positive allosteric modulators of the benzodiazepine binding sites of GABAA receptors, and have hypnotic-based sedation and anti-anxiety effects [<xref rid="B1-ijerph-20-05373" ref-type="bibr">1</xref>]. These drugs are frequently used as hypnotics or anxiolytics for those with insomnia, general anxiety disorder (GAD), and panic disorder. They are also commonly prescribed for anxiety symptoms, and not just for insomnia and anxiety spectrum disorders, which might lead to potentially inappropriate medications [<xref rid="B2-ijerph-20-05373" ref-type="bibr">2</xref>]. Moreover, BZDs are commonly prescribed for individuals with psychiatric disorders, such as schizophrenia and bipolar disorder, to manage psychiatric symptoms, including agitation and aggression [<xref rid="B3-ijerph-20-05373" ref-type="bibr">3</xref>].</p><p>The long-term use of BZDs has disadvantages such as dependence, decline in cognitive function, and motor impairment, leading to hip fractures associated with falls [<xref rid="B4-ijerph-20-05373" ref-type="bibr">4</xref>,<xref rid="B5-ijerph-20-05373" ref-type="bibr">5</xref>,<xref rid="B6-ijerph-20-05373" ref-type="bibr">6</xref>,<xref rid="B7-ijerph-20-05373" ref-type="bibr">7</xref>]. With regard to the treatment of insomnia, clinical guidelines recommend cognitive behavioral therapy for insomnia (CBT-I) as the first-line treatment, and medications including BZDs should only be considered if CBT-I is ineffective or unavailable [<xref rid="B8-ijerph-20-05373" ref-type="bibr">8</xref>,<xref rid="B9-ijerph-20-05373" ref-type="bibr">9</xref>]. It has also been suggested that BZDs should only be used for a short period of up to four weeks [<xref rid="B9-ijerph-20-05373" ref-type="bibr">9</xref>]. Despite these evidence-based recommendations, BZDs continue to be repeatedly prescribed worldwide. </p><p>The prescription of BZDs is higher in Japan than in Western countries, according to a 2010 United Nations report [<xref rid="B10-ijerph-20-05373" ref-type="bibr">10</xref>]. The country&#8217;s universal healthcare coverage, which provides easy access to medical care and ensures a low financial burden, may make it difficult for healthcare providers and users to be mindful not to prescribe or use unnecessary BDZ [<xref rid="B11-ijerph-20-05373" ref-type="bibr">11</xref>]. Given this situation, the Japanese government implemented medical fee reductions for BDZs use three times between 2012 and 2018 to promote appropriate use (1 April 2012, 1 April 2014, and 1 April 2018). However, according to a survey using a large-scale health insurance claims database conducted in 2021 by Takeshima et al., the mean duration of hypnotic prescriptions was 2.9&#8201;months, and 9.3% of patients were prescribed hypnotics for 12 months [<xref rid="B11-ijerph-20-05373" ref-type="bibr">11</xref>]. Moreover, an observational study using a Japan Medical Data Center dataset containing all medical fee data of health insurance service subscribers from 2015 to 2019 showed that the prescription of high-potency hypnotics (&gt;15 mg/day diazepam) and anxiolytics (&gt;2 mg/day flunitrazepam) generally remained unchanged [<xref rid="B12-ijerph-20-05373" ref-type="bibr">12</xref>]. These results suggest that the Japanese policies did not significantly affect long-term and high-dose BZD use. Consequently, safe tapering or discontinuation of BZD is a crucial and urgent issue in clinical settings.</p><p>In recent years, traditional patient&#8211;clinician interaction that focused on the &#8220;expert&#8221; healthcare provider informing the patient on the best course of action for a specific treatment has been replaced with patient-centered approaches, such as shared treatment decision making [<xref rid="B13-ijerph-20-05373" ref-type="bibr">13</xref>,<xref rid="B14-ijerph-20-05373" ref-type="bibr">14</xref>]. In line with this, prescribing behavior becomes more equal in concordance based on a partnership between the patient and clinician, where the reflection of the patient&#8217;s opinion on the medication regimen is fully considered during the decision-making process [<xref rid="B15-ijerph-20-05373" ref-type="bibr">15</xref>]. Patient participation in self-healthcare decisions is an ethical imperative [<xref rid="B16-ijerph-20-05373" ref-type="bibr">16</xref>] and should be recognized as a right [<xref rid="B17-ijerph-20-05373" ref-type="bibr">17</xref>]. Several countries and federal initiatives have promoted shared decision making as a desirable medical approach [<xref rid="B18-ijerph-20-05373" ref-type="bibr">18</xref>,<xref rid="B19-ijerph-20-05373" ref-type="bibr">19</xref>,<xref rid="B20-ijerph-20-05373" ref-type="bibr">20</xref>,<xref rid="B21-ijerph-20-05373" ref-type="bibr">21</xref>]. Japanese clinical guidelines for schizophrenia, depression, and social anxiety disorder also recommend implementing shared decision making in practice [<xref rid="B22-ijerph-20-05373" ref-type="bibr">22</xref>,<xref rid="B23-ijerph-20-05373" ref-type="bibr">23</xref>,<xref rid="B24-ijerph-20-05373" ref-type="bibr">24</xref>].</p><p>Patients are willing to be aware of their illness and participate in the decision-making process [<xref rid="B25-ijerph-20-05373" ref-type="bibr">25</xref>]. This tendency has no exception in psychiatry [<xref rid="B26-ijerph-20-05373" ref-type="bibr">26</xref>]. Such a patient-centered approach has the potential to reduce the overuse of treatment options, including choice of medication, which does not benefit everyone [<xref rid="B27-ijerph-20-05373" ref-type="bibr">27</xref>]. </p><p>However, patient involvement in treatment decision making in clinical settings is not fully understood. The extent to which patients are involved in prescribing behaviors related to BZD use remains unclear. Considering the long-term and high-dose use of BZDs, patient involvement may not be implemented in psychiatry in Japan.</p><p>This study aimed to assess the perceptions of BZD use and decision making regarding discontinuation of BZDs between psychiatric outpatients and psychiatrists. Considering the long-term and high-dose use of BZDs, we hypothesized that there might be discrepancies between the outpatients and psychiatrists regarding BZD use and discontinuation.</p></sec><sec id="sec2-ijerph-20-05373"><title>2. Materials and Methods</title><sec id="sec2dot1-ijerph-20-05373"><title>2.1. Study Design</title><p>We performed a cross-sectional, anonymous survey.</p><p>For psychiatric outpatients, we included members of the Mental Health and Welfare Bonding Organization (COMHBO), which is a nonprofit community organization comprising individuals with mental illnesses, such as schizophrenia and bipolar disorder, their families, and formal/informal caregivers. An invitation was sent to individuals with mental illnesses (<italic toggle="yes">n</italic> = 740) on 25 October 2021 via COMHBO email listservs with a link to the as a Google Forms survey. Those who met the following criteria were invited to participate in this survey: aged 20 years or above and currently on hypnotic/anxiolytic regimen or having taken hypnotic/anxiolytic drugs in the past. A reminder email was sent after two weeks, and the survey was closed on 26 November 2021.</p><p>We included psychiatrists belonging to the Japanese Association of Neuro-Psychiatric Clinics (<italic toggle="yes">n</italic> = 1690). An invitation was sent to each psychiatrist on 10 January 2022 via email listservs of the association, which included a link to the as Google Forms survey. We also dispatched each psychiatrist the survey by post to enable them to respond by whichever mode they preferred. The survey was closed on 26 January 2022.</p><p>This study was approved by the Institutional Review Board of St. Luke&#8217;s International University (2021-604).</p></sec><sec id="sec2dot2-ijerph-20-05373"><title>2.2. Questionnaire and Statistical Analysis</title><p>The variables for the questionnaire were developed based on a literature review and discussions within the steering group of this study, including psychiatrists, a psychiatric nurse, and an outpatient with mental illness. The questionnaire consisted of the following components: (1) demographics; (2) current situation related to hypnotic/anxiolytic use, such as experience, duration, and the number of hypnotic/anxiolytic medications taken; (3) perspectives of hypnotic/anxiolytic use (desirable timing of reduction after symptom improvement and permissible situation of its continuation); (4) decision making regarding the continuing/tapering of hypnotic/anxiolytic use; and (5) difficulties when attempting to reduce hypnotic/anxiolytic use in the past. Regarding each variable, anxiolytics were benzodiazepines and hypnotics included both benzodiazepines and z-drugs (<xref rid="app1-ijerph-20-05373" ref-type="app">Supplement File S1</xref>). We then used descriptive statistics (mean and frequency) to investigate each item. The chi-square (&#967;<sup>2</sup>) test was used to compare outpatients&#8217; responses to those of psychiatrists&#8217; regarding the decisions on continuing/tapering hypnotic/anxiolytics. The results were considered statistically significant at <italic toggle="yes">p</italic> &#8804; 0.05.</p></sec></sec><sec sec-type="results" id="sec3-ijerph-20-05373"><title>3. Results</title><sec id="sec3dot1-ijerph-20-05373"><title>3.1. Demographics</title><p>In total, 104 psychiatric outpatients and 543 psychiatrists completed the survey. <xref rid="ijerph-20-05373-t001" ref-type="table">Table 1</xref> shows the respondents&#8217; demographic details and other characteristics.</p></sec><sec id="sec3dot2-ijerph-20-05373"><title>3.2. Outpatients&#8217; Reported Current Situation of Hypnotic/Anxiolytic Use</title><p>Overall, 52.9% of outpatient respondents reported that they had taken both hypnotics/anxiolytics, while 30.8% had hypnotics only and 16.4% had anxiolytics only. Regarding the duration of taking hypnotics/anxiolytics, 92.0% of outpatient respondents reported that they had taken hypnotics for over a year, and 95.8% had anxiolytics for more than one year (<xref rid="ijerph-20-05373-t002" ref-type="table">Table 2</xref>).</p></sec><sec id="sec3dot3-ijerph-20-05373"><title>3.3. Perspectives of Hypnotic/Anxiolytic Use</title><sec id="sec3dot3dot1-ijerph-20-05373"><title>3.3.1. Desirable Timing of Reduction after Symptom Improvement</title><p>The most frequent response of the outpatients was &#8220;no need to reduce hypnotic/anxiolytic if there are no side effects&#8221; (23.1%), followed by &#8220;immediately after symptom improvement&#8221; (19.2%), and &#8220;within 3 months after symptom improvement&#8221; (16.4%). On the other hand, 49.16% of outpatients desired to reduce hypnotic/anxiolytic usage within 12 months after symptom improvement, who constitute the participants that selected one of the following four variables: &#8220;immediately&#8221; (19.2%), &#8220;within 3 months&#8221; (16.4%), &#8220;within 6 months&#8221; (3.9%), and &#8220;within 12 months(9.6%).&#8221;</p><p>The most desirable reduction timing of hypnotic/anxiolytic use for the psychiatrists after patient&#8217;s symptom improvement was &#8220;within 3 months after symptom improvement&#8221; (38.1%), followed by &#8220;within 6 months after symptom improvement&#8221; (22.5 %), and &#8220;immediately after symptom improvement&#8221; (14.2%). Overall, 85.5% of psychiatrists desired to reduce hypnotic/anxiolytic use immediately within 12 months after symptom improvement as a total of four variables: &#8220;immediately&#8221; (14.2%), &#8220;within 3 months&#8221; (38.1%), &#8220;within 6 months&#8221; (22.5%), and &#8220;within 12 months&#8221; (8.3%).</p><p>In comparing the two groups, some variables included discrepancies: more psychiatrists thought that hypnotic/anxiolytic reduction should occur &#8220;within 3 months&#8221; (<italic toggle="yes">p</italic> &lt; 0.001) and &#8220;within 6 months&#8221; (<italic toggle="yes">p</italic> &lt; 0.001) compared to outpatients, while more outpatients thought that the reduction should occur &#8220;after 12 months passed&#8221; (<italic toggle="yes">p</italic> &lt; 0.001) and &#8220;no need to reduce if there are no side effects&#8221; (<italic toggle="yes">p</italic> &lt; 0.001) compared to psychiatrists (<xref rid="ijerph-20-05373-t003" ref-type="table">Table 3</xref>).</p></sec><sec id="sec3dot3dot2-ijerph-20-05373"><title>3.3.2. Permissible Situation of Hypnotic/Anxiolytic Continuation</title><p>The most frequent answer by both the outpatients and psychiatrists was &#8220;when I (the patient) am (is) still suffering from symptoms of insomnia or anxiety&#8221; (71.2% of outpatients, 69.8% of psychiatrists), followed by &#8220;when my (the patient&#8217;s) social functioning is disrupted&#8221; (39.4% of outpatients, 55.1% of psychiatrists) and &#8220;when I (the patient) still have (has) physical or mental problem, which led to the start of the medication administration&#8221; (31.7% of outpatients, 47.0% of psychiatrists).</p><p>In comparing the two groups, there were discrepancies in three variables: psychiatrists were more careful about &#8220;social functioning disruption&#8221; (<italic toggle="yes">p</italic> &lt; 0.001) and &#8220;physical and mental problems, which led them to start to take the medication&#8221; (<italic toggle="yes">p</italic> &lt; 0.001), and &#8220;the number of medications taken&#8221; (<italic toggle="yes">p</italic> &lt; 0.001) compared to the patients (<xref rid="ijerph-20-05373-t003" ref-type="table">Table 3</xref>).</p></sec><sec id="sec3dot3dot3-ijerph-20-05373"><title>3.3.3. Decisions Making Regarding Continuing/Tapering Hypnotic/Anxiolytic Use</title><p>The ranking of the outpatients and psychiatrists was consistent, as follows: &#8220;the outpatient and psychiatrist make (made) the decision together, on an equal basis&#8221; (44.1% of outpatients, 79.6% of psychiatrists), followed by &#8220;the decision is (was) made, considering the psychiatrist&#8217;s opinion&#8221; (31.7% of outpatients, 16.6% of psychiatrists) and &#8220;the decision is (was) made, considering the patient&#8217;s opinion&#8221;(24.0% of outpatients, 3.5% of psychiatrists). In contrast, there was a significant difference between the proportion of outpatient respondents and psychiatrists for each variable. Thus, our hypothesis that there would be a discrepancy between outpatients and psychiatrists was accepted. Most psychiatrists thought that they made decisions on continuing/tapering hypnotic/anxiolytics using shared decision making on an equal basis, while the majority of outpatients believed that they made a decision considering the psychiatrist&#8217;s opinion. (<xref rid="ijerph-20-05373-t004" ref-type="table">Table 4</xref>).</p></sec></sec><sec id="sec3dot4-ijerph-20-05373"><title>3.4. Difficulties When Trying to Reduce Hypnotic/Anxiolytic in the Past</title><p>The most frequent difficulty of the outpatients was &#8220;I could not reduce the medication because withdrawal symptoms appeared when I tried&#8221; (24.0%), followed by &#8220;I could not reduce the medication because of worsening symptoms&#8221; (23.1%) and &#8220;I never had any particular problem regarding the medication reduction&#8221; (21.2%). Moreover, the outpatients experienced the following difficulties because of insufficient related information: &#8220;I did not know how to reduce the medication&#8221; (18.3%), &#8220;I did not know when I should reduce the medication&#8221; (19.2%), and &#8220;I did not know the situation or condition where the medication could be reduced&#8221; (14.4%). </p><p>The most frequent answer of the psychiatrists was &#8220;I could not reduce the medication because the patient was unwilling to reduce it&#8221; (78.8%), followed by &#8220;I could not reduce the medication because of worsening symptoms&#8221; (61.3%) and &#8220;I could not reduce the medication because withdrawal symptoms appeared when I tried&#8221; (37.6%).</p><p>In comparing the two groups, most items had discrepancies: more outpatients felt that they did not know &#8220;how to reduce the medication&#8221; (<italic toggle="yes">p</italic> &lt; 0.001), &#8220;when I should reduce the medication&#8221; (<italic toggle="yes">p</italic> &lt; 0.001), and &#8220;the situation or condition where the medication can be reduced&#8221; (<italic toggle="yes">p</italic> &lt; 0.001) due to insufficient information compared to the psychiatrists. On the other hand, more psychiatrists felt that they could not reduce the medication because of &#8220;worsening symptoms&#8221; (<italic toggle="yes">p</italic> &lt; 0.001) and &#8220;withdrawal symptoms appeared when tried&#8221; (<italic toggle="yes">p</italic> &lt; 0.001) compared to the patients (<xref rid="ijerph-20-05373-t005" ref-type="table">Table 5</xref>).</p></sec></sec><sec sec-type="discussion" id="sec4-ijerph-20-05373"><title>4. Discussion</title><p>This is the first study to assess and compare perceptions of BZD use and decision making regarding its discontinuation between psychiatric outpatients and psychiatrists.</p><p>In this study, almost half of the psychiatric outpatients (49.1%) and the majority of the psychiatrists (85.5%) desired to reduce hypnotic/anxiolytic use within 12 months of symptom improvement. In particular, psychiatrists were more willing to implement medication reduction if they thought that the reduction should occur &#8220;within 3 months&#8221; (<italic toggle="yes">p</italic> &lt; 0.001) and &#8220;within 6 months&#8221; (<italic toggle="yes">p</italic> &lt; 0.001) compared to outpatients. Thus, the stakeholders&#8217; preferences were in line with the recommendations described in several clinical guidelines, which recommend that hypnotics/anxiolytics should not be prescribed for a longer time [<xref rid="B8-ijerph-20-05373" ref-type="bibr">8</xref>,<xref rid="B9-ijerph-20-05373" ref-type="bibr">9</xref>,<xref rid="B10-ijerph-20-05373" ref-type="bibr">10</xref>]. However, against their will, more than 90% of the outpatients remained on the hypnotic/anxiolytic for over 12 months. Most psychiatrists thought they could not reduce the medication because the patient was unwilling to. Moreover, a certain number of the outpatients felt that they had not been provided with sufficient information regarding hypnotic/anxiolytic usage reduction. This suggests that there should be more emphasis on sharing related information with the patients. Heather et al. reported that those with insomnia who received a letter warning about the harms of long-term use of BZD hypnotics showed larger reductions in BZD consumption than those who did not [<xref rid="B22-ijerph-20-05373" ref-type="bibr">22</xref>]. Accordingly, sharing not only the advantages, but also the disadvantages of hypnotic/anxiolytic behavior with individuals taking them might lead to successful medication reduction. In this context, shared treatment decision making is expected to be promoted in the clinical setting. </p><p>This study found discrepancies between the perspectives of outpatients and psychiatrists. Thus, our hypothesis was accepted. First, more psychiatrists perceived permissible situations for hypnotic/anxiolytic continuation in relation to social functioning and physical or mental problems, which led to the start of the medication, compared to the patients. Second, more psychiatrists found worsening psychiatric and withdrawal symptoms challenging while attempting to reduce medication compared to the patients. These results suggest that patients may not focus on symptoms and function, whereas psychiatrists do. Thus, these discrepancies mean that psychiatrists might fail to understand the patient&#8217;s preferences and values, which should be clarified through conversation with the patients in a clinical setting. Third, more psychiatrists felt that they had already implemented shared decision making, while more patients felt that the decision had been made considering the psychiatrists&#8217; opinions. This discrepancy is crucial because SDM may not be as widely implemented as psychiatrists believe. Several studies have reported similar situations. For instance, Matthias et al. observed appointments in psychiatric outpatient services for medication management and found that psychiatrists initiated most of the decisions [<xref rid="B28-ijerph-20-05373" ref-type="bibr">28</xref>]. Verwijmeren et al. also indicated that the degree of objective patient involvement in psychiatric consultations was low [<xref rid="B29-ijerph-20-05373" ref-type="bibr">29</xref>]. Accordingly, both psychiatrists and patients must understand these situations and discrepancies, which suggests that patient participation to clarify their preferences and values regarding BZD discontinuation should be encouraged in the clinical setting.</p><p>Based on the results of this study, we propose some solutions for the current situation in Japan, where long-term and high-dose BZD use remains. First, &gt;90% of the patients in this study had used hypnotic/anxiolytic medication for over a year. Other countries have already set limits on the duration of BZD prescriptions at four weeks [<xref rid="B30-ijerph-20-05373" ref-type="bibr">30</xref>,<xref rid="B31-ijerph-20-05373" ref-type="bibr">31</xref>,<xref rid="B32-ijerph-20-05373" ref-type="bibr">32</xref>,<xref rid="B33-ijerph-20-05373" ref-type="bibr">33</xref>,<xref rid="B34-ijerph-20-05373" ref-type="bibr">34</xref>,<xref rid="B35-ijerph-20-05373" ref-type="bibr">35</xref>,<xref rid="B36-ijerph-20-05373" ref-type="bibr">36</xref>]. Therefore, it may be necessary to review our medical system, which has no duration limit and allows for long-term BZD use. Second, the results revealed that some psychiatrists still preferred long-term BZD use and believed there was no need to reduce if there were no side effects. Twenty-three percent of patients also felt no need to reduce it. For instance, the health system could introduce regular warning signs on medical records if BDZ use is longer than four weeks to promote awareness of the preferred short-term use of BDZs. Third, our results showed that most psychiatrists believed BZD use should be reduced early after symptom improvement. We must develop a system to put this positive perspective into practice. For example, communication support tools, such as patient decision aids [<xref rid="B37-ijerph-20-05373" ref-type="bibr">37</xref>], might be useful in discussing whether to continue or discontinue BZDs during consultation. Moreover, an inter-professional approach should also be considered. Other healthcare providers, such as pharmacists and nurses, could support patients in deliberating whether to continue or discontinue BDZ medication by providing related information on each treatment option neutrally [<xref rid="B38-ijerph-20-05373" ref-type="bibr">38</xref>,<xref rid="B39-ijerph-20-05373" ref-type="bibr">39</xref>]. Thus, it may be desirable to adopt such a policy of patient involvement during BZD discontinuation and reduce reimbursement as a national policy.</p><p>This study had several limitations. First, outpatients and psychiatrists were recruited from different organizations. The findings might have been different if the study had been conducted with a combination of the psychiatrist in charge and their patients. Second, outpatients in this study had mental health conditions, such as schizophrenia and bipolar disorder. The results may have differed with patients under primary care because mental illness is considered a risk factor for the long-term use of BZDs [<xref rid="B40-ijerph-20-05373" ref-type="bibr">40</xref>,<xref rid="B41-ijerph-20-05373" ref-type="bibr">41</xref>,<xref rid="B42-ijerph-20-05373" ref-type="bibr">42</xref>]. Third, the sample size of psychiatrists was approximately five times higher than that of participants. Fourth, psychiatrists were older than the outpatients, and male psychiatrists predominated. Differences in age and sex may lead to different perspectives and attitudes. Thus, these sociodemographic factors may have affected the study outcomes. Fifth, we did not examine patients&#8217; characteristics, such as medical history and past and current medications. Sixth, regarding the item &#8216;I could not reduce the medication because the patient was unwilling to reduce it&#8217; as difficulties while attempting to reduce hypnotic/anxiolytic in the past, we did not collect the patients&#8217; data. Thus, we could not compare the perceptions of the two parties. Nonetheless, this study is valuable in the current situation, wherein the issue of long-term BZD use remains unresolved.</p></sec><sec sec-type="conclusions" id="sec5-ijerph-20-05373"><title>5. Conclusions</title><p>This study assessed and compared the perceptions on BZD use and decision making regarding its discontinuation between psychiatric outpatients and psychiatrists. The results suggest that the majority of psychiatric outpatients were taking hypnotics/anxiolytics for a long time against their will. There might be a difference in perception toward hypnotic/anxiolytic use and decision making for its discontinuation between psychiatric outpatients and psychiatrists. Further research is required to address this gap.</p></sec></body><back><ack><title>Acknowledgments</title><p>We sincerely thank the respondents for participating in this study. We sincerely express our gratitude to the Community Mental Health and Welfare Bonding Organization of Japan.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-ijerph-20-05373"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/article/10.3390/ijerph20075373/s1">https://www.mdpi.com/article/10.3390/ijerph20075373/s1</uri>, Supplementary File S1.</p><supplementary-material id="ijerph-20-05373-s001" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ijerph-20-05373-s001.zip" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>All authors (Y.A., M.T., T.T., E.K., K.U., K.I., K.W., K.M. and Y.T.) contributed towards the concept and design of the study. Y.T. contributed to the funding acquisition. Y.T., E.K. and K.U. conducted the acquisition of the data through conducting the web-based surveys. Y.A. conducted the statistical analysis, with M.T. and Y.T. contributing to the analysis. Y.A. prepared the first draft of the manuscript, with all other authors (M.T., T.T., E.K., K.U., K.I., K.W., K.M. and Y.T.) contributing towards the review and approval of the final draft. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board of the St. Luke&#8217;s International University (2021-604).</p></notes><notes><title>Informed Consent Statement</title><p>Informed consent was obtained from all subjects involved in the study.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The datasets are available from the corresponding author on reasonable request.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>Yumi Aoki declares no conflict of interest. Masahiro Takeshima has received speaker&#8217;s honoraria from Takeda Pharmaceutical, Otsuka Pharmaceutical, Daiichi Sankyo Company, Sumitomo Pharma, Meiji Seika Pharma, Viatris Pharmaceuticals Japan, Eisai, Ltd. and Yoshitomi Pharmaceutical, and research grants from Otsuka Pharmaceutical, Eisai, Shionogi and the Japanese Ministry of Health, Labour and Welfare (R3-21GC1016) outside the submitted work. Takashi Tsuboi received personal fees from Eisai, Kyowa Pharmaceutical Industry, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, Mochida, Otsuka, Shionogi, Sumitomo Pharma, Takeda Pharmaceutical, Viatris, and Yoshitomiyakuhin in the last three years. Eiichi Katsumoto received speaker&#8217;s honoraria from Sumitomo Pharma Co., Ltd., Takeda Pharmaceutical Company Limited., Otsuka Pharmaceutical Co., Ltd., Eisai Co., Ltd., K.K, Kyowa Pharmaceutical Industry Co., Ltd., Viatris Inc., Janssen Pharmaceutical K.K., Yoshitomiyakuhin Corporation, Mitsubishi Tanabe Pharma Corporation, Meiji Seika Pharma Co., Ltd., Pfizer Japan Inc., Lundbeck Japan K.K., Towa Pharmaceutical Co., Ltd., and Eli Lilly Japan K.K. in the last three years. Ken Udagawa declares no conflicts of interest. Ken Inada has received personal fees/grant support from Eisai, Eli Lilly, Janssen, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, Mochida, Novartis, Otsuka, Shionogi, Sumitomo Pharma, and Yoshitomiyakuhin in the last three years. Koichiro Watanabe received manuscript fees or speaker&#8217;s honoraria from Eisai, Eli Lilly, Janssen Pharmaceutical, Kyowa Pharmaceutical, Lundbeck Japan, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, Otsuka Pharmaceutical, Pfizer, Shionogi, Sumitomo Pharma, and Takeda Pharmaceutical, and received research/grant support from Daiichi Sankyo, Eisai, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, Otsuka Pharmaceutical, Pfizer, Sumitomo Pharma, and Takeda Pharmaceutical. In addition, KW is a consultant of Boehringer Ingelheim, Daiichi Sankyo, Eisai, Eli Lilly, Janssen Pharmaceutical, Kyowa Pharmaceutical, Lundbeck Japan, Luye Pharma, Mitsubishi Tanabe Pharma, Otsuka Pharmaceutical, Pfizer, Sumitomo Dainippon Pharma, Taisho Toyama Pharmaceutical, and Takeda Pharmaceutical. Kazuo Mishima has received speaker&#8217;s honoraria from EISAI Co., Ltd., Nobelpharma Co., Ltd., Takeda Pharmaceutical Co., Ltd., Inc. and research grants from Eisai Co., Ltd., Sumitomo Pharma Co., Ltd., Takeda Pharmaceutical Co., Ltd., AMED (JP21 dk0307103 KM), the Japanese Ministry of Health, Labour, and Welfare (19 GC1012, 21 GC0801). Yoshikazu Takaesu received a lecture sponsorship from Takeda Pharmaceutical, Sumitomo Pharma, Otsuka Pharmaceutical, Meiji Seika Pharma, Kyowa Pharmaceutical, Eisai, and Yoshitomi and research funding from Otsuka Pharmaceutical, Meiji Seika Pharma, and Eisai.</p></notes><ref-list><title>References</title><ref id="B1-ijerph-20-05373"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sigel</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ernst</surname><given-names>M.</given-names></name></person-group><article-title>The Benzodiazepine Binding Sites of GABAA Receptors</article-title><source>Trends Pharmacol. Sci.</source><year>2018</year><volume>39</volume><fpage>659</fpage><lpage>671</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2018.03.006</pub-id><pub-id pub-id-type="pmid">29716746</pub-id></element-citation></ref><ref id="B2-ijerph-20-05373"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Drusch</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tri</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Ankri</surname><given-names>J.</given-names></name><name name-style="western"><surname>Michelon</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zureik</surname><given-names>M.</given-names></name><name name-style="western"><surname>Herr</surname><given-names>M.</given-names></name></person-group><article-title>Potentially inappropriate medications in nursing homes and the community older adults using the French health insurance database</article-title><source>Pharmacoepidemiol. Drug Saf.</source><year>2023</year><volume>32</volume><fpage>475</fpage><lpage>485</lpage><pub-id pub-id-type="doi">10.1002/pds.5575</pub-id><pub-id pub-id-type="pmid">36424189</pub-id></element-citation></ref><ref id="B3-ijerph-20-05373"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brunette</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Noordsy</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>H.</given-names></name><name name-style="western"><surname>Drake</surname><given-names>R.E.</given-names></name></person-group><article-title>Benzodiazepine use and abuse among patients with severe mental illness and co-occurring substance use disorders</article-title><source>Psychiatr. Serv.</source><year>2003</year><volume>54</volume><fpage>1395</fpage><lpage>1401</lpage><pub-id pub-id-type="doi">10.1176/appi.ps.54.10.1395</pub-id><pub-id pub-id-type="pmid">14557527</pub-id></element-citation></ref><ref id="B4-ijerph-20-05373"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>GBD 2017 Disease and Injury Incidence and Prevalence Collaborators</collab></person-group><article-title>Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990&#8211;2017: A systematic analysis for the global burden of disease study 2017</article-title><source>Lancet</source><year>2018</year><volume>392</volume><fpage>1789</fpage><lpage>1858</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(18)32279-7</pub-id><pub-id pub-id-type="pmid">30496104</pub-id><pub-id pub-id-type="pmcid">PMC6227754</pub-id></element-citation></ref><ref id="B5-ijerph-20-05373"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rickels</surname><given-names>K.</given-names></name><name name-style="western"><surname>Case</surname><given-names>W.G.</given-names></name><name name-style="western"><surname>Downing</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Winokur</surname><given-names>A.</given-names></name></person-group><article-title>Long-term diazepam therapy and clinical outcome</article-title><source>JAMA</source><year>1983</year><volume>250</volume><fpage>767</fpage><lpage>771</lpage><pub-id pub-id-type="doi">10.1001/jama.1983.03340060045024</pub-id><pub-id pub-id-type="pmid">6348314</pub-id></element-citation></ref><ref id="B6-ijerph-20-05373"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Picton</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Marino</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Nealy</surname><given-names>K.L.</given-names></name></person-group><article-title>Benzodiazepine use and cognitive decline in the elderly</article-title><source>Am. J. Health Syst. Pharm.</source><year>2018</year><volume>75</volume><fpage>e6</fpage><lpage>e12</lpage><pub-id pub-id-type="doi">10.2146/ajhp160381</pub-id><pub-id pub-id-type="pmid">29273607</pub-id></element-citation></ref><ref id="B7-ijerph-20-05373"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Woolcott</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Wiens</surname><given-names>M.O.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>B.</given-names></name><name name-style="western"><surname>Marin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Marra</surname><given-names>C.A.</given-names></name></person-group><article-title>Meta-analysis of the impact of 9 medication classes on falls in elderly persons</article-title><source>Arch. Intern. Med.</source><year>2009</year><volume>169</volume><fpage>1952</fpage><lpage>1960</lpage><comment>Erratum in <italic toggle="yes">Arch. Intern. Med.</italic><bold>2010</bold>, <italic toggle="yes">170</italic>, 477</comment><pub-id pub-id-type="doi">10.1001/archinternmed.2009.357</pub-id><pub-id pub-id-type="pmid">19933955</pub-id></element-citation></ref><ref id="B8-ijerph-20-05373"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xing</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X.L.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J.X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name></person-group><article-title>Association between use of benzodiazepines and risk of fractures: A meta-analysis</article-title><source>Osteoporos. Int.</source><year>2014</year><volume>25</volume><fpage>105</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1007/s00198-013-2446-y</pub-id><pub-id pub-id-type="pmid">24013517</pub-id></element-citation></ref><ref id="B9-ijerph-20-05373"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schutte-Rodin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Broch</surname><given-names>L.</given-names></name><name name-style="western"><surname>Buysse</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dorsey</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sateia</surname><given-names>M.</given-names></name></person-group><article-title>Clinical guideline for the evaluation and management of chronic insomnia in adults</article-title><source>J. Clin. Sleep Med.</source><year>2008</year><volume>4</volume><fpage>487</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.5664/jcsm.27286</pub-id><pub-id pub-id-type="pmid">18853708</pub-id><pub-id pub-id-type="pmcid">PMC2576317</pub-id></element-citation></ref><ref id="B10-ijerph-20-05373"><label>10.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>International Narcotics Control Board UN</collab></person-group><source>Report of the International Narcotics Control Board on the Availability of Internationally Controlled Drugs: Ensuring Adequate Access for Medical and Scientific Purposes</source><publisher-name>INCB</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>2010</year></element-citation></ref><ref id="B11-ijerph-20-05373"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takeshima</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yoshizawa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Enomoto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ogasawara</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kudo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Itoh</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ayabe</surname><given-names>N.</given-names></name><name name-style="western"><surname>Takaesu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mishima</surname><given-names>K.</given-names></name></person-group><article-title>Effects of Japanese policies and novel hypnotics on long-term prescriptions of hypnotics</article-title><source>Psychiatry Clin. Neurosci.</source><year>2022</year><comment><italic toggle="yes">Early View</italic></comment><pub-id pub-id-type="doi">10.1111/pcn.13525</pub-id><pub-id pub-id-type="pmcid">PMC11488605</pub-id><pub-id pub-id-type="pmid">36579672</pub-id></element-citation></ref><ref id="B12-ijerph-20-05373"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shinfuku</surname><given-names>N.</given-names></name></person-group><article-title>Analysis of the trends of polypharmacy and high-dose prescriptions in Japan</article-title><source>Asia Pac. Psychiatry</source><year>2022</year><volume>14</volume><fpage>e12488</fpage><pub-id pub-id-type="doi">10.1111/appy.12488</pub-id><pub-id pub-id-type="pmid">34519433</pub-id><pub-id pub-id-type="pmcid">PMC9285042</pub-id></element-citation></ref><ref id="B13-ijerph-20-05373"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>L&#233;gar&#233;</surname><given-names>F.</given-names></name><name name-style="western"><surname>Adekpedjou</surname><given-names>R.</given-names></name><name name-style="western"><surname>Stacey</surname><given-names>D.</given-names></name><name name-style="western"><surname>Turcotte</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kryworuchko</surname><given-names>J.</given-names></name><name name-style="western"><surname>Graham</surname><given-names>I.D.</given-names></name><name name-style="western"><surname>Lyddiatt</surname><given-names>A.</given-names></name><name name-style="western"><surname>Politi</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Thomson</surname><given-names>R.</given-names></name><name name-style="western"><surname>Elwyn</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Interventions for increasing the use of shared decision making by healthcare professionals</article-title><source>Cochrane Database Syst. Rev.</source><year>2018</year><volume>7</volume><fpage>CD006732</fpage><pub-id pub-id-type="doi">10.1002/14651858.CD006732.pub4</pub-id><pub-id pub-id-type="pmid">30025154</pub-id><pub-id pub-id-type="pmcid">PMC6513543</pub-id></element-citation></ref><ref id="B14-ijerph-20-05373"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aoki</surname><given-names>Y.</given-names></name></person-group><article-title>Shared decision making for adults with severe mental illness: A concept analysis</article-title><source>Jpn. J. Nurs. Sci.</source><year>2020</year><volume>17</volume><fpage>e12365</fpage><pub-id pub-id-type="doi">10.1111/jjns.12365</pub-id><pub-id pub-id-type="pmid">32761783</pub-id><pub-id pub-id-type="pmcid">PMC7590107</pub-id></element-citation></ref><ref id="B15-ijerph-20-05373"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bond</surname><given-names>C.</given-names></name><name name-style="western"><surname>Blenkinsopp</surname><given-names>A.</given-names></name><name name-style="western"><surname>Raynor</surname><given-names>D.K.</given-names></name></person-group><article-title>Prescribing and partnership with patients</article-title><source>Br. J. Clin. Pharmacol.</source><year>2012</year><volume>74</volume><fpage>581</fpage><lpage>588</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.2012.04330.x</pub-id><pub-id pub-id-type="pmid">22621201</pub-id><pub-id pub-id-type="pmcid">PMC3477325</pub-id></element-citation></ref><ref id="B16-ijerph-20-05373"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Drake</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Deegan</surname><given-names>P.E.</given-names></name></person-group><article-title>Shared decision making is an ethical imperative</article-title><source>Psychiatr. Serv.</source><year>2009</year><volume>60</volume><fpage>1007</fpage><pub-id pub-id-type="doi">10.1176/ps.2009.60.8.1007</pub-id><pub-id pub-id-type="pmid">19648184</pub-id></element-citation></ref><ref id="B17-ijerph-20-05373"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Straub</surname><given-names>C.</given-names></name><name name-style="western"><surname>Nebling</surname><given-names>T.</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>H.</given-names></name></person-group><article-title>Translating research into practice: A German sickness fund supporting patient participation</article-title><source>Patient Educ. Couns.</source><year>2008</year><volume>73</volume><fpage>544</fpage><lpage>550</lpage><pub-id pub-id-type="doi">10.1016/j.pec.2008.07.019</pub-id><pub-id pub-id-type="pmid">18718732</pub-id></element-citation></ref><ref id="B18-ijerph-20-05373"><label>18.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Shafir</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rosenthal</surname><given-names>J.</given-names></name></person-group><source>Shared Decision Making: Advancing Patient-Centered Care through State and Federal Implementation</source><publisher-name>National Academy for State Health Policy</publisher-name><publisher-loc>Portland, ME, USA</publisher-loc><year>2012</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.nashp.org/wp-content/uploads/sites/default/files/shared.decision.making.report.pdf" ext-link-type="uri">https://www.nashp.org/wp-content/uploads/sites/default/files/shared.decision.making.report.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-11-30">(accessed on 30 November 2022)</date-in-citation></element-citation></ref><ref id="B19-ijerph-20-05373"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joseph-Williams</surname><given-names>N.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wood</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lloyd</surname><given-names>A.</given-names></name><name name-style="western"><surname>Brain</surname><given-names>K.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>N.</given-names></name><name name-style="western"><surname>Prichard</surname><given-names>A.</given-names></name><name name-style="western"><surname>Goodland</surname><given-names>A.</given-names></name><name name-style="western"><surname>McGarrigle</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sweetland</surname><given-names>H.</given-names></name><etal/></person-group><article-title>A descriptive model of shared decision making derived from routine implementation in clinical practice (&#8216;Implement-SDM&#8217;): Qualitative study</article-title><source>Patient Educ. Couns.</source><year>2019</year><volume>102</volume><fpage>1774</fpage><lpage>1785</lpage><pub-id pub-id-type="doi">10.1016/j.pec.2019.07.016</pub-id><pub-id pub-id-type="pmid">31351787</pub-id></element-citation></ref><ref id="B20-ijerph-20-05373"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spatz</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Krumholz</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Moulton</surname><given-names>B.W.</given-names></name></person-group><article-title>Prime time for shared decision making</article-title><source>JAMA</source><year>2017</year><volume>317</volume><fpage>1309</fpage><lpage>1310</lpage><pub-id pub-id-type="doi">10.1001/jama.2017.0616</pub-id><pub-id pub-id-type="pmid">28384834</pub-id></element-citation></ref><ref id="B21-ijerph-20-05373"><label>21.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Alston</surname><given-names>C.</given-names></name><name name-style="western"><surname>Berger</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Brownlee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Elwyn</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fowler</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>L.K.</given-names></name><name name-style="western"><surname>Montori</surname><given-names>V.M.</given-names></name><name name-style="western"><surname>Moulton</surname><given-names>B.</given-names></name><name name-style="western"><surname>Paget</surname><given-names>L.</given-names></name><name name-style="western"><surname>Haviland-Shebel</surname><given-names>B.</given-names></name></person-group><source>Shared Decision-Making Strategies for Best Care: Patient Decision Aids</source><publisher-name>National Academy of Medicine</publisher-name><publisher-loc>Washington, DC, USA</publisher-loc><year>2014</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://nam.edu/wp-content/uploads/2015/06/SDMforBestCare2.pdf" ext-link-type="uri">https://nam.edu/wp-content/uploads/2015/06/SDMforBestCare2.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-11-30">(accessed on 30 November 2022)</date-in-citation></element-citation></ref><ref id="B22-ijerph-20-05373"><label>22.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>The Japanese Society of Mood Disorders</collab></person-group><source>The Depression Treatment Guidelines</source><edition>2nd ed.</edition><publisher-name>APA</publisher-name><publisher-loc>Washington, DC, USA</publisher-loc><year>2016</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.secretariat.ne.jp/jsmd/iinkai/katsudou/data/20190724-02.pdf" ext-link-type="uri">https://www.secretariat.ne.jp/jsmd/iinkai/katsudou/data/20190724-02.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-02-26">(accessed on 26 February 2023)</date-in-citation></element-citation></ref><ref id="B23-ijerph-20-05373"><label>23.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>The Japanese Society of Neuropsychopharmacology</collab></person-group><article-title>The Schizophrenia Treatment Guidelines</article-title><year>2022</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.jsnp-org.jp/csrinfo/03_2.html" ext-link-type="uri">https://www.jsnp-org.jp/csrinfo/03_2.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-02-26">(accessed on 26 February 2023)</date-in-citation></element-citation></ref><ref id="B24-ijerph-20-05373"><label>24.</label><element-citation publication-type="webpage"><article-title>The Japanese Society of Anxiety and Related Disorders &amp; The Japanese Society of Neuropsychopharmacology, The Social Anxiety Disorder Treatment Guidelines</article-title><year>2021</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://minds.jcqhc.or.jp/docs/gl_pdf/G0001312/4/Social_anxiety_disorder.pdf" ext-link-type="uri">https://minds.jcqhc.or.jp/docs/gl_pdf/G0001312/4/Social_anxiety_disorder.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-02-26">(accessed on 26 February 2023)</date-in-citation></element-citation></ref><ref id="B25-ijerph-20-05373"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mulley</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Trimble</surname><given-names>C.</given-names></name><name name-style="western"><surname>Elwyn</surname><given-names>G.</given-names></name></person-group><article-title>Stop the silent misdiagnosis: Patients&#8217; preferences matter</article-title><source>BMJ</source><year>2012</year><volume>345</volume><fpage>e6572</fpage><pub-id pub-id-type="doi">10.1136/bmj.e6572</pub-id><pub-id pub-id-type="pmid">23137819</pub-id></element-citation></ref><ref id="B26-ijerph-20-05373"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamann</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Leucht</surname><given-names>S.</given-names></name><name name-style="western"><surname>Busch</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kissling</surname><given-names>W.</given-names></name></person-group><article-title>Do patients with schizophrenia wish to be involved in decisions about their medical treatment?</article-title><source>Am. J. Psychiatry</source><year>2005</year><volume>162</volume><fpage>2382</fpage><lpage>2384</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.162.12.2382</pub-id><pub-id pub-id-type="pmid">16330606</pub-id></element-citation></ref><ref id="B27-ijerph-20-05373"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heather</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bowie</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ashton</surname><given-names>H.</given-names></name><name name-style="western"><surname>McAvoy</surname><given-names>B.</given-names></name><name name-style="western"><surname>Spencer</surname><given-names>I.</given-names></name><name name-style="western"><surname>Brodie</surname><given-names>J.</given-names></name><name name-style="western"><surname>Giddingset</surname><given-names>D.</given-names></name></person-group><article-title>Randomised controlled trial of two brief interventions against long-term benzodiazepine use: Outcome of intervention</article-title><source>Addict. Res. Theory</source><year>2004</year><volume>12</volume><fpage>141</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1080/1606635310001634528</pub-id></element-citation></ref><ref id="B28-ijerph-20-05373"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matthias</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Salyers</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Rollins</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Frankel</surname><given-names>R.M.</given-names></name></person-group><article-title>Decision making in recovery-oriented mental health care</article-title><source>Psychiatr. Rehabil. J.</source><year>2012</year><volume>35</volume><fpage>305</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.2975/35.4.2012.305.314</pub-id><pub-id pub-id-type="pmid">22491370</pub-id><pub-id pub-id-type="pmcid">PMC3980461</pub-id></element-citation></ref><ref id="B29-ijerph-20-05373"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verwijmeren</surname><given-names>D.</given-names></name><name name-style="western"><surname>Grootens</surname><given-names>K.P.</given-names></name></person-group><article-title>Shared decision making in pharmacotherapy decisions, perceived by patients with bipolar disorder</article-title><source>Int. J. Bipolar. Disord.</source><year>2018</year><volume>6</volume><fpage>21</fpage><pub-id pub-id-type="doi">10.1186/s40345-018-0129-5</pub-id><pub-id pub-id-type="pmid">30284089</pub-id><pub-id pub-id-type="pmcid">PMC6170516</pub-id></element-citation></ref><ref id="B30-ijerph-20-05373"><label>30.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>National Institute for Clinical Excellence</collab></person-group><article-title>Guidance on the Use of Zaleplon, Zolpidem and Zopiclone for the Short-Term Management of Insomnia. Nice Guideline (TA77)</article-title><year>2004</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.nice.org.uk/guidance/ta77/resources/guidance-on-the-use-of-zaleplonzolpidem-and-zopiclone-for-the-shortterm-management-of-insomnia-pdf2294763557317" ext-link-type="uri">https://www.nice.org.uk/guidance/ta77/resources/guidance-on-the-use-of-zaleplonzolpidem-and-zopiclone-for-the-shortterm-management-of-insomnia-pdf2294763557317</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-02-26">(accessed on 26 February 2023)</date-in-citation></element-citation></ref><ref id="B31-ijerph-20-05373"><label>31.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>National Institute for Clinical Excellence</collab></person-group><article-title>Generalised Anxiety Disorder and Panic Disorder in Adults: Management. Nice Guideline (CG113)</article-title><year>2011</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.nice.org.uk/guidance/CG113" ext-link-type="uri">https://www.nice.org.uk/guidance/CG113</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-02-26">(accessed on 26 February 2023)</date-in-citation></element-citation></ref><ref id="B32-ijerph-20-05373"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lai</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Bleidt</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Singh-Franco</surname><given-names>D.</given-names></name><name name-style="western"><surname>Elusma</surname><given-names>C.</given-names></name><name name-style="western"><surname>Huh</surname><given-names>G.</given-names></name></person-group><article-title>Trends in benzodiazepine prescribing under Medicare part D in USA: Outpatient settings 2005&#8211;2009</article-title><source>J. Pharm. Health Serv.</source><year>2015</year><volume>6</volume><fpage>133</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1111/jphs.12098</pub-id></element-citation></ref><ref id="B33-ijerph-20-05373"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stubbings</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lau</surname><given-names>D.T.</given-names></name></person-group><article-title>Medicare part D research highlights and policy updates, 2013: Impact and insights</article-title><source>Clin. Ther.</source><year>2013</year><volume>35</volume><fpage>402</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1016/j.clinthera.2013.02.024</pub-id><pub-id pub-id-type="pmid">23541710</pub-id></element-citation></ref><ref id="B34-ijerph-20-05373"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoebert</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Souverein</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Mantel-Teeuwisse</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Leufkens</surname><given-names>H.G.M.</given-names></name><name name-style="western"><surname>Van Dijk</surname><given-names>L.</given-names></name></person-group><article-title>Reimbursement restriction and moderate decrease in benzodiazepine use in general practice</article-title><source>Ann. Fam. Med.</source><year>2012</year><volume>10</volume><fpage>42</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1370/afm.1319</pub-id><pub-id pub-id-type="pmid">22230829</pub-id><pub-id pub-id-type="pmcid">PMC3262472</pub-id></element-citation></ref><ref id="B35-ijerph-20-05373"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rat</surname><given-names>C.</given-names></name><name name-style="western"><surname>Penhouet</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gaultier</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chaslerie</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pivette</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Victorri-Vigneau</surname><given-names>C.</given-names></name></person-group><article-title>Did the new French pay-for performance system modify benzodiazepine prescribing practices?</article-title><source>BMC Health Serv. Res.</source><year>2014</year><volume>14</volume><elocation-id>301</elocation-id><pub-id pub-id-type="doi">10.1186/1472-6963-14-301</pub-id><pub-id pub-id-type="pmid">25011548</pub-id><pub-id pub-id-type="pmcid">PMC4105521</pub-id></element-citation></ref><ref id="B36-ijerph-20-05373"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Panes</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pariente</surname><given-names>A.</given-names></name><name name-style="western"><surname>B&#233;nard-Laribi&#232;re</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lassalle</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dureau-Pournin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lorrain</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tournier</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fourrier-R&#233;glat</surname><given-names>A.</given-names></name></person-group><article-title>Use of benzodiazepines and z-drugs not compliant with guidelines and associated factors: A population based study</article-title><source>Eur. Arch. Psychiatry Clin. Neurosci.</source><year>2020</year><volume>270</volume><fpage>3</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1007/s00406-018-0966-3</pub-id><pub-id pub-id-type="pmid">30539229</pub-id></element-citation></ref><ref id="B37-ijerph-20-05373"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aoki</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Takaesu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Okajima</surname><given-names>I.</given-names></name><name name-style="western"><surname>Takeshima</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shimura</surname><given-names>A.</given-names></name><name name-style="western"><surname>Utsumi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kotorii</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yamashita</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kuriyama</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Development and acceptability of a decision aid for chronic insomnia considering discontinuation of benzodiazepine hypnotics</article-title><source>Neuropsychopharmacol. Rep.</source><year>2022</year><volume>42</volume><fpage>10</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1002/npr2.12219</pub-id><pub-id pub-id-type="pmid">34807524</pub-id><pub-id pub-id-type="pmcid">PMC8919126</pub-id></element-citation></ref><ref id="B38-ijerph-20-05373"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jull</surname><given-names>J.</given-names></name><name name-style="western"><surname>K&#246;pke</surname><given-names>S.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>M.</given-names></name><name name-style="western"><surname>Carley</surname><given-names>M.</given-names></name><name name-style="western"><surname>Finderup</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rahn</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Boland</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dunn</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dwyer</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Kasper</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Decision coaching for people making healthcare decisions</article-title><source>Cochrane Database Syst. Rev.</source><year>2021</year><volume>11</volume><fpage>CD013385</fpage><pub-id pub-id-type="doi">10.1002/14651858.CD013385</pub-id><pub-id pub-id-type="pmid">34749427</pub-id><pub-id pub-id-type="pmcid">PMC8575556</pub-id></element-citation></ref><ref id="B39-ijerph-20-05373"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jull</surname><given-names>J.</given-names></name><name name-style="western"><surname>Finderup</surname><given-names>J.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kienlin</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Rahn</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Dunn</surname><given-names>S.</given-names></name><name name-style="western"><surname>Aoki</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>L.</given-names></name><name name-style="western"><surname>Harvey</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Understanding how and under what circumstances decision coaching works for people making healthcare decisions: A realist review</article-title><source>BMC Med. Inform. Decis. Mak.</source><year>2022</year><volume>22</volume><elocation-id>265</elocation-id><pub-id pub-id-type="doi">10.1186/s12911-022-02007-0</pub-id><pub-id pub-id-type="pmid">36209086</pub-id><pub-id pub-id-type="pmcid">PMC9548102</pub-id></element-citation></ref><ref id="B40-ijerph-20-05373"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Gerlach</surname><given-names>L.B.</given-names></name><name name-style="western"><surname>Van</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yosef</surname><given-names>M.</given-names></name><name name-style="western"><surname>Conroy</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Zivin</surname><given-names>K.</given-names></name></person-group><article-title>Predictors of Long-Term and High-Dose Use of Zolpidem in Veterans</article-title><source>J. Clin. Psychiatry</source><year>2019</year><volume>80</volume><fpage>18m12149</fpage><pub-id pub-id-type="doi">10.4088/JCP.18m12149</pub-id><pub-id pub-id-type="pmid">30840786</pub-id></element-citation></ref><ref id="B41-ijerph-20-05373"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takeshima</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ogawa</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hayasaka</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Furukawa</surname><given-names>T.A.</given-names></name></person-group><article-title>Continuation and discontinuation of benzodiazepine prescriptions: A cohort study based on a large claims database in Japan</article-title><source>Psychiatry Res.</source><year>2016</year><volume>237</volume><fpage>201</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1016/j.psychres.2016.01.040</pub-id><pub-id pub-id-type="pmid">26805564</pub-id></element-citation></ref><ref id="B42-ijerph-20-05373"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takano</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ono</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yamana</surname><given-names>H.</given-names></name><name name-style="western"><surname>Matsui</surname><given-names>H.</given-names></name><name name-style="western"><surname>Matsumoto</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yasunaga</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kawakami</surname><given-names>N.</given-names></name></person-group><article-title>Factors associated with long-term prescription of benzodiazepine: A retrospective cohort study using a health insurance database in Japan</article-title><source>BMJ Open</source><year>2019</year><volume>9</volume><fpage>e029641</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2019-029641</pub-id><pub-id pub-id-type="pmcid">PMC6661576</pub-id><pub-id pub-id-type="pmid">31350250</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap position="float" id="ijerph-20-05373-t001" orientation="portrait"><object-id pub-id-type="pii">ijerph-20-05373-t001_Table 1</object-id><label>Table 1</label><caption><p>Demographic details and other characteristics of the respondents.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Variables</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Outpatients <italic toggle="yes">n</italic> = 104</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Psychiatrists <italic toggle="yes">n</italic> = 543</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> Value *</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Sex, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Female</td><td align="center" valign="middle" rowspan="1" colspan="1">57 (54.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">107 (19.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Male</td><td align="center" valign="middle" rowspan="1" colspan="1">46 (44.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">433 (79.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Other</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (0.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.626</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Age (years), <italic toggle="yes">n</italic> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">20&#8211;29</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (2.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">30&#8211;39</td><td align="center" valign="middle" rowspan="1" colspan="1">22 (21.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">11 (2.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">40&#8211;49</td><td align="center" valign="middle" rowspan="1" colspan="1">42 (40.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">70 (12.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">50&#8211;59</td><td align="center" valign="middle" rowspan="1" colspan="1">31 (29.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">153(28.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.736</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">60&#8211;69</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (4.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">195(35.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">70&#8211;79</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">96(17.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">&#8805;80</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">15(2.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.086</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">N.A.</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (0.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Service used/affiliation, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Clinic</td><td align="center" valign="middle" rowspan="1" colspan="1">54 (51.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">536 (98.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Psychiatric hospital</td><td align="center" valign="middle" rowspan="1" colspan="1">34 (32.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (0.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">General hospital</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (7.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (0.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">University hospital</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (7.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">N.A.</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (0.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Psychiatric diagnosis, <italic toggle="yes">n</italic> (%) **</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Schizophrenia</td><td align="center" valign="middle" rowspan="1" colspan="1">47 (45.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Bipolar disorder</td><td align="center" valign="middle" rowspan="1" colspan="1">25 (24.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Major depressive disorder</td><td align="center" valign="middle" rowspan="1" colspan="1">19 (18.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Anxiety disorder</td><td align="center" valign="middle" rowspan="1" colspan="1">14 (13.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Developmental disorder</td><td align="center" valign="middle" rowspan="1" colspan="1">13 (12.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Insomnia</td><td align="center" valign="middle" rowspan="1" colspan="1">12 (11.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Other</td><td align="center" valign="middle" rowspan="1" colspan="1">10 (9.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unknown</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (2.9)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr></tbody></table><table-wrap-foot><fn><p>* Based on &#967;<sup>2</sup> test, ** Multiple answers, N.A.: No answer.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="ijerph-20-05373-t002" orientation="portrait"><object-id pub-id-type="pii">ijerph-20-05373-t002_Table 2</object-id><label>Table 2</label><caption><p>Response of outpatients pertaining to the current situation of hypnotic/anxiolytic use.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Variable</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Experience of taking hypnotic/anxiolytic, <italic toggle="yes">n</italic> (%), <italic toggle="yes">n</italic> = 104</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hypnotic only</td><td align="center" valign="middle" rowspan="1" colspan="1">32 (30.8)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Anxiolytic only</td><td align="center" valign="middle" rowspan="1" colspan="1">17 (16.3)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Both hypnotic/anxiolytic</td><td align="center" valign="middle" rowspan="1" colspan="1">55 (52.9)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Duration of taking hypnotic, <italic toggle="yes">n</italic> (%), <italic toggle="yes">n</italic> = 87</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">&lt;1 month</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1.2)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">1&#8211;3 months</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (4.6)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">3&#8211;6 months</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (2.3)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">6&#8211;12 months</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">&#8805;12 months</td><td align="center" valign="middle" rowspan="1" colspan="1">80 (92.0)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Duration of taking anxiolytic, <italic toggle="yes">n</italic> (%), <italic toggle="yes">n</italic> = 72</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">&lt;1 month</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (2.8)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">1&#8211;3 months</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">3&#8211;6 months</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">6&#8211;12 months</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1.4)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">&#8805;12 months</td><td align="center" valign="middle" rowspan="1" colspan="1">69 (95.8)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Numbers taking hypnotic, <italic toggle="yes">n</italic> (%), <italic toggle="yes">n</italic> = 87</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">44 (50.6)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">28 (32.2)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (6.9)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">&#8805;4</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (10.3)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Numbers taking anxiolytic, <italic toggle="yes">n</italic> (%), <italic toggle="yes">n</italic> = 72</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">40 (55.6)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">20 (27.8)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (5.6)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8805; 4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8 (11.1)</td></tr></tbody></table></table-wrap><table-wrap position="float" id="ijerph-20-05373-t003" orientation="portrait"><object-id pub-id-type="pii">ijerph-20-05373-t003_Table 3</object-id><label>Table 3</label><caption><p>Perspectives related to hypnotic/anxiolytic use.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Variables</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Outpatients<break/><italic toggle="yes">n</italic> = 104</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Psychiatrists<break/><italic toggle="yes">n</italic> = 543</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> Value *</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Desirable timing of hypnotic/anxiolytic reduction after symptom improvement, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Immediately</td><td align="center" valign="middle" rowspan="1" colspan="1">20 (19.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">77 (14.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.186</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Within 3 months</td><td align="center" valign="middle" rowspan="1" colspan="1">17 (16.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">207 (38.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Within 6 months</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (3.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">122 (22.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Within 12 months</td><td align="center" valign="middle" rowspan="1" colspan="1">10 (9.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">45 (8.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.656</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">After 12 months passed</td><td align="center" valign="middle" rowspan="1" colspan="1">11 (10.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">13 (2.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">No need to reduce if there are no side effects</td><td align="center" valign="middle" rowspan="1" colspan="1">24 (23.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">26 (4.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Other</td><td align="center" valign="middle" rowspan="1" colspan="1">10 (9.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">44 (8.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.609</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Unknown/N.A.</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (7.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (1.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Permissible situation of hypnotic/anxiolytic continuation **</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">When I (the patient) am (is) still suffering from symptoms of insomnia or anxiety</td><td align="center" valign="middle" rowspan="1" colspan="1">74 (71.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">379 (69.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.782</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">When my (the patient&#8217;s) social functioning is disrupted</td><td align="center" valign="middle" rowspan="1" colspan="1">41 (39.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">299 (55.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">When I (the patient) still have (has) physical or mental problem, which led to start to take the medication</td><td align="center" valign="middle" rowspan="1" colspan="1">33 (31.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">255 (47.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">When I (the patient) want(s) to continue the medication</td><td align="center" valign="middle" rowspan="1" colspan="1">32 (30.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">121 (22.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.062</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">When I (the patient) am (is) not suffering from side effects of the medication</td><td align="center" valign="middle" rowspan="1" colspan="1">29 (27.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">149 (27.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.926</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">When my (the patient&#8217;s) quality of life is worsened</td><td align="center" valign="middle" rowspan="1" colspan="1">25 (24.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">93 (17.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.095</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">When the number of medications I (the patient) am (is) taking is low</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (7.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">157 (28.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Other</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (4.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">11 (2.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.094</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unknown/N.A.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (1.9)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (0.6)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.144</td></tr></tbody></table><table-wrap-foot><fn><p>* Based on &#967;<sup>2</sup> test, ** Multiple answers, N.A.: No answer.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="ijerph-20-05373-t004" orientation="portrait"><object-id pub-id-type="pii">ijerph-20-05373-t004_Table 4</object-id><label>Table 4</label><caption><p>Decision making regarding continuing/tapering hypnotic/anxiolytic use.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Variables</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Outpatients<break/><italic toggle="yes">n</italic> = 104</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Psychiatrists<break/><italic toggle="yes">n</italic> = 541</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> Value *</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">The decision is (was) made, considering the patient&#8217;s opinion</td><td align="center" valign="middle" rowspan="1" colspan="1">33 (31.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">90 (16.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">The outpatient and psychiatrist make (made) the decision together, on an equal basis</td><td align="center" valign="middle" rowspan="1" colspan="1">46 (44.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">432 (79.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The decision is (was) made, considering the psychiatrist&#8217;s opinion</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25 (24.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19 (3.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr></tbody></table><table-wrap-foot><fn><p>* Based on &#967;<sup>2</sup> test.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="ijerph-20-05373-t005" orientation="portrait"><object-id pub-id-type="pii">ijerph-20-05373-t005_Table 5</object-id><label>Table 5</label><caption><p>Difficulties cited while attempting to reduce hypnotic/anxiolytic in the past (multiple answers).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Variable</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Outpatients<break/><italic toggle="yes">n</italic> = 104</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Psychiatrists<break/><italic toggle="yes">n</italic> = 543</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> Value *</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">I could not reduce the medication because the patient was unwilling to reduce it</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">428 (78.8) </td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">I did not know how to reduce the medication due to insufficient related information (provided by psychiatrist)</td><td align="center" valign="middle" rowspan="1" colspan="1">19 (18.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (1.5) </td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">I did not know when I should reduce the medication due to insufficient related information (provided by psychiatrist)</td><td align="center" valign="middle" rowspan="1" colspan="1">20 (19.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">14 (2.6) </td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">I did not know the situation or condition, where the medication can be reduced due to insufficient related information (provided by psychiatrist)</td><td align="center" valign="middle" rowspan="1" colspan="1">15 (14.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">25 (4.6) </td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">I could not reduce the medication because of worsening symptoms</td><td align="center" valign="middle" rowspan="1" colspan="1">24 (23.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">333 (61.3) </td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">I could not reduce the medication because withdrawal symptoms (e.g., tremors, palpitations, anxiety) appeared when I tried to reduce </td><td align="center" valign="middle" rowspan="1" colspan="1">25 (24.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">204 (37.6) </td><td align="center" valign="middle" rowspan="1" colspan="1">0.008</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">I never had any particular problem regarding the medication reduction</td><td align="center" valign="middle" rowspan="1" colspan="1">22 (21.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">34 (6.3) </td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">I never reduced the medication</td><td align="center" valign="middle" rowspan="1" colspan="1">15 (14.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.2) </td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Other</td><td align="center" valign="middle" rowspan="1" colspan="1">11 (10.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">12 (2.2) </td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N.A.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">34 (6.3) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr></tbody></table><table-wrap-foot><fn><p>* Based on &#967;<sup>2</sup> test, N.A.: No answer.</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>